ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines...
Progress across the pipeline in multiple clinical trials, includingPhase 2 program of GEO-CM04S1...
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire...
ATLANTA, GA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...
Intellectual Property Assets Strengthened for Cancer Immunotherapy Programand for Marburg Virus and HIV...
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Feb. 06...
ATLANTA, GA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...
Strengthening GeoVax’s Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE...
Therapy Demonstrated Safety, Stabilization/Shrinkage of Treated Tumors Expanded Development for Monotherapy...
Patent Covers Multiple Component Vaccine for Both Prevention and Treatment ATLANTA, GA, Jan. 03, 2024 (GLOBE...
ATLANTA, GA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a...
ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...
80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model ATLANTA, GA, Nov. 30, 2023 (GLOBE...
ATLANTA, GA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.